Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Acceleron Pharma Inc. (NASDAQ: XLRN).

Full DD Report for XLRN

You must become a subscriber to view this report.


Recent News from (NASDAQ: XLRN)

Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspatercept at the 23 rd Congress of the European Hematology Associ...
Source: Business Wire
Date: May, 17 2018 09:21
Scholar Rock Readies $75 Million IPO
Quick Take Scholar Rock Holding ( SRRK ) intends to raise $75 million in an IPO of its common stock, according to an SEC regulatory filing . The company is advancing a pipeline of drug treatment candidates for muscle-wasting and cancer diseases. While SRRK has a promising collaboratio...
Source: SeekingAlpha
Date: May, 15 2018 13:01
Acceleron Pharma's (XLRN) CEO Habib Dable on Q1 2018 Results - Earnings Call Transcript
Acceleron Pharma Inc. (XLRN) Q1 2018 Earnings Conference Call May 8, 2018 17:00 PM ET Executives Todd James - Vice President, Investor Relations and Corporate Communications Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Matthew Sherman - Chief...
Source: SeekingAlpha
Date: May, 14 2018 02:00
Acceleron Pharma Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 10 2018 14:37
Acceleron Pharma beats by $0.06, misses on revenue
Acceleron Pharma (NASDAQ: XLRN ): Q1 EPS of -$0.58 beats by $0.06 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:35
Acceleron Reports First Quarter 2018 Operating and Financial Results
– Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept expected in mid-2018 – – ACE-083 advances into Part 2 of the ongoing Phase 2 trial in facioscapulohumeral muscular dystrophy – – PULSAR Phase 2 trial with sotatercept...
Source: Business Wire
Date: May, 08 2018 16:01
A Fresh Look At Celgene After Q1 And New Info On Ozanimod
Introduction - A perplexing stock This article covers issues about Celgene (CELG) that are on my mind, some of which may be on the minds of various investors, large and small. This stock was one of my few significant investment disappointments last year in what was otherwise a very fine year...
Source: SeekingAlpha
Date: May, 08 2018 05:10
Scholar Rock Seeks $75 Million In U.S. IPO
Quick Take Scholar Rock (SRRK) intends to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The firm is a preclinical firm developing treatments for muscle-wasting and diseases and cancers. SRRK is well-funded and has a promising collaborati...
Source: SeekingAlpha
Date: May, 04 2018 14:01
Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase - New Research Emphasizes Economic Growth
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sonic Automotive, Inc. (NYSE:SAH), STERIS plc (NYSE:STE), AquaVenture Hold...
Source: GlobeNewswire
Date: May, 03 2018 07:55
2 Attractive Biotech Stocks To Buy Now
T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss .” ― Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w...
Source: SeekingAlpha
Date: May, 02 2018 10:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1734.6934.7034.899934.07249,507
2017-03-1030.3929.871330.683729.7982,090
2017-03-0929.3830.0731.0528.88949,201
2017-03-0827.1328.3828.8127.13479,076
2017-03-0728.9927.1129.5727.04426,823

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1437,86745,92382.4576Short
2018-08-1348,28862,22177.6072Short
2018-08-1039,16360,50664.7258Short
2018-08-0943,67266,50565.6672Short
2018-08-0891,904135,57967.7863Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on XLRN.


About Acceleron Pharma Inc. (NASDAQ: XLRN)

Logo for Acceleron Pharma Inc. (NASDAQ: XLRN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,616,918,572 - 05/11/2018
  • Issue and Outstanding: 45,419,061 - 01/31/2018

 


Recent Filings from (NASDAQ: XLRN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 13 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: XLRN)

Daily Technical Chart for (NASDAQ: XLRN)


Stay tuned for daily updates and more on (NASDAQ: XLRN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: XLRN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in XLRN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of XLRN and does not buy, sell, or trade any shares of XLRN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/